Keyphrases
18F-DOPA PET
6%
Advanced Parkinson's Disease
10%
Biochemical Markers
6%
Clinical Characteristics
8%
Clinical Features
6%
Columbia University
13%
Deep Brain Stimulation Surgery
12%
Differential Screening
6%
Disease Severity
11%
Disease-related
7%
Essential Tremor
18%
Ethnic Cluster
6%
Fall Risk
6%
G2019S
7%
G2019S mutation
14%
Gait
6%
Healthy Controls
7%
Hebrew Version
12%
Huntington's Disease
12%
Idiopathic Parkinson's Disease
10%
Interferon-α (IFN-α)
6%
IPX066
6%
Israel
12%
Karaites
6%
Leucine-rich Repeat Kinase 2 (LRRK2)
52%
LRRK2 Gene
9%
Metabolic Syndrome
6%
Mountain Jews
6%
Movement Disorder Society
7%
Movement Disorders
17%
MS Patients
6%
Mutation Carriers
10%
Neuroblastoma
6%
Neurogenesis
6%
Nocturnal Movements
6%
Non-associated
12%
Non-carriers
7%
Non-manifesting Carriers
20%
Parkinson Patients
23%
Parkinson's Disease
100%
Parkinson's Disease Risk
6%
Parkinsonism
6%
Patient Characteristics
7%
Patients with Parkinson's Disease
23%
Prodromal Parkinson's Disease
6%
Tremor
9%
Tremor Disease
7%
Unified Dyskinesia Rating Scale
6%
Unified Parkinson's Disease Rating Scale (UPDRS)
7%
University Medical Centre
12%
Medicine and Dentistry
Amantadine
6%
Clinician
6%
Diagnosis of Parkinson's Disease
6%
Dyskinesia
6%
Electrical Brain Stimulation
12%
Essential Tremor
12%
Fiber Optics
6%
Fluorine-18
6%
Heart Innervation
6%
Huntington's Disease
12%
Infusion
6%
Metabolic Syndrome
6%
Parkinson's Disease
38%
Parkinsonism
6%
Plummer-Vinson Syndrome
6%
Positron Emission Tomography
6%
Rating Scale
12%
Stereotypic Movement Disorder
15%